The soft tissue malignancies include myxoid liposarcoma, 157 myxoid malignant fibrous histiocytoma 158 and its allied lesions, low-grade fibromyxoid sarcoma 159, 160 and low-grade myofibroblastic sarcoma, 161 myxoid chondrosarcoma, 158, 162 myxoid peripheral nerve sheath tumors, 139 myxoid rhabdomyosarcoma, 163 malignant myoepithelioma, 164 myxoid synovial sarcoma, 165 myxoid follicular dendritic cell sarcoma, 166 myxoid dermatofibrosarcoma protuberans, 167 metastatic chordoma, and its benign mimic, parachordoma
Counteracting Corticosteroid Damage: A significant clinical advantage of BPC-157 is its ability to heal muscle and connective tissue even in the presence of systemic corticosteroids (which usually inhibit repair)
Worked example 2 the 30 mg vial Concentration: 30 mg 3 mL = 10 mg/mL Starting 2 mg dose: 2 mg 10 mg/mL = 0.20 mL = 20 units At 4 mg: 0.40 mL = 40 units | at 8 mg: 0.80 mL = 80 units | at 12 mg: 1.20 mL = 120 units Notice the higher-strength 30 mg build keeps every draw small the 20 mg, 24 mg and 30 mg vials all reconstitute to the same tidy 10 mg/mL, which is why they are convenient for higher maintenance doses
An employer cannot discriminate in favor of highly compensated employees if the HRA is a group health plan subject to nondiscrimination rules under the Internal Revenue Code (IRC) Section 105(h)
